Hexarelin vs HGH
Well Studied vs FDA Approved
requires timing Mechanism-based · 51% GH secretagogues and exogenous GH compete via negative feedback. Exogenous GH suppresses natural GH pulses, reducing secretagogue efficacy. If combining, administer the secretagogue first and separate by 2+ hours.
Molecular Data
Hexarelin HGH
Weight 887 Da 22,124 Da
Half-life 1-2 hours 3-4 hours (SC), 20-30 minutes (IV)
Chain 6 amino acids 191 amino acids
Type Synthetic hexapeptide Single-chain polypeptide with two disulfide bridges
Key Benefits
Hexarelin
01 Most potent GHRP for GH stimulation
02 Powerful synergy with GHRH peptides
03 Cardioprotective effects via CD36 receptor
04 Enhanced muscle growth and strength
05 Improved fat metabolism
06 Better recovery and tissue repair
07 Maintains natural GH pulsatility
08 Stable against proteolytic enzymes
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Dosing Protocols
Hexarelin
100-200 mcg per injection / 2-3 times daily for optimal GH pulses
GH optimization 100 mcg 2-3x daily
Enhanced results 200 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Cardioprotection 100-200 mcg 1-2x daily
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Side Effects
Hexarelin
Increased appetite (less than GHRP-6)
Water retention
Tingling or numbness
Tiredness after injection
Mild headache
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
WADA prohibited for competitive athletes
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Research Evidence
Hexarelin HGH
Status Well Studied FDA Approved
References 4 studies 4 studies
Latest — 2024
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.